Angiotensin II-driven coronary vasculopathy and pressure-overload myocardial remodeling represent distinct vascular

Dzmitry Matsiukevich1,2, David M Ornitz1

  • 1Department of Developmental Biology, Washington University in St. Louis School of Medicine, St. Louis, MO, United States.

Insights

Chronic activation of the renin-angiotensin-aldosterone system (RAAS) promotes cardiac remodeling. This study reveals that hemodynamic stress causes myocardial changes, while angiotensin II (AngII) drives vascular smooth muscle cell (VSMC)-centric vasculopathy.

Area of Science:

  • Cardiovascular Biology
  • Renal Physiology
  • Vascular Biology

Background:

  • Chronic renin-angiotensin-aldosterone system (RAAS) activation contributes to pathological cardiac and coronary artery remodeling.
  • Mechanisms differentiating myocardial from vascular remodeling under RAAS activation are not fully understood.

Purpose of the Study:

  • To investigate the distinct roles of hemodynamic versus neurohumoral stress in cardiac remodeling.
  • To emphasize the impact on coronary vasculopathy and vascular smooth muscle cell (VSMC) plasticity.

Main Methods:

  • Utilized three murine models: transverse aortic constriction (TAC), angiotensin II (AngII) plus phenylephrine (AngII/PE), and high-dose AngII (HD-AngII).
  • Assessed hemodynamics via catheterization and quantified remodeling using histology and immunostaining, including VSMC phenotype, proliferation, and fibrosis.

Main Results:

  • All models showed diastolic dysfunction and myocardial fibrosis; TAC induced higher systolic pressure than AngII models.
  • AngII-driven remodeling shifted towards a VSMC-centric vasculopathy, characterized by VSMC dedifferentiation, proliferation, neointima formation, and elastic lamina injury.
  • AngII exposure led to greater myocardial fibrosis at lower pressures compared to TAC, with localized hypertrophy near fibrotic regions.

Conclusions:

  • Hemodynamic pressure overload (TAC) and AngII-driven neurohumoral stress induce distinct cardiac remodeling phenotypes.
  • TAC primarily causes uniform myocardial hypertrophy and interstitial fibrosis.
  • Chronic AngII exposure preferentially promotes VSMC-centric coronary vasculopathy with perivascular fibrosis and elastic lamina injury, offering insights into targeted therapies.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...